Biological characterisation and comparison of patients with multiple osseous or lymphogenous metastasised prostate cancer and with bone metastases from other primary tumours/ histology

Biological characterisation and comparison of patients with multiple osseous or lymphogenous metastasised prostate cancer and with bone metastases from other primary tumours/ histology - Poly-CR-P

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035620

Enrollment

100

Registered

2024-11-28

Start date

2023-04-26

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C79

Interventions

Group 1: Patients with metastatic prostate cancer who are already been treated with androgen deprivation and who received local curatively-intended therapy (surgery or radiotherapy) after first diagno

after the last fraction of radiotherapy

3 months after end of radiotherapy or 3 months after start of systemic therapy). If available, already obtained biomaterials (primary tumours, tissue samples from metastases) should be used for the st

Eligibility

Sex/Gender

All

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: Cohort 1: • Patients with histologically confirmed prostate carcinoma (adenocarcinoma) • Previous local therapy with curative intention • PSMA-PET-CT for re-staging with evidence of > 5 metastases • Interdisciplinary tumour board decision with recommendation to change therapy • No other active tumour disease Cohort 2: • Patients with histologically confirmed renal cell carcinoma or squamous cell carcinoma. • Previous local therapy with curative intention • Staging with evidence of >/= 3 metastases • Interdisciplinary tumour board decision with recommendation for therapy • No other active tumour diseases

Exclusion criteria

Exclusion criteria: Cohort 1: • age < 40 yrs • No consent for data analysis • Histology other than adenocarcinoma Cohort 2: • age < 40 yrs • No consent for data analysis

Design outcomes

Primary

Measure	Time frame
Cohort 1: Analyses of the expression profiles of CTCs, proteins and nucleic acids in patients with osseous metastatic pattern and comparison to patients with lymphogenic metastatic pattern. Cohort 1 and 2: Comparison of the expression profiles of circulating tumour cells (CTCs) and other biological characteristics (see above) of patients with prostate carcinoma with patients with metastases from other primary tumours/histologies.	—

Measure

Time frame

Cohort 1: Analyses of the expression profiles of CTCs, proteins and nucleic acids in patients with osseous metastatic pattern and comparison to patients with lymphogenic metastatic pattern. Cohort 1 and 2: Comparison of the expression profiles of circulating tumour cells (CTCs) and other biological characteristics (see above) of patients with prostate carcinoma with patients with metastases from other primary tumours/histologies.

—

Secondary

Measure	Time frame
Cohort 1: PSA response to systemic therapy in correlation with number and characteristics of CTCs. Cohort 1 and 2: Clinical progression in correlation with number and characteristics of CTCs.	—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026